4,504 results match your criteria Plaque Psoriasis


Risankizumab: A Review in Moderate to Severe Plaque Psoriasis.

Authors:
Hannah A Blair

Drugs 2020 Jul 6. Epub 2020 Jul 6.

Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.

Risankizumab (Skyrizi; risankizumab-rzaa) is a humanized immunoglobulin (Ig) G1 monoclonal antibody that specifically targets the p19 subunit of interleukin (IL)-23, thereby inhibiting IL-23-dependent cell signaling. Subcutaneous risankizumab is approved for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy (in the EU), those who are candidates for systemic therapy or phototherapy (in the USA) and those who have an inadequate response to conventional therapies (in Japan). In pivotal phase III trials (UltIMMa-1, UltIMMa-2, IMMvent and IMMhance), risankizumab was more effective than placebo, ustekinumab and adalimumab with regard to the proportion of patients achieving ≥ 90% improvement from baseline in Psoriasis Area and Severity Index score (PASI 90) and a static Physician's Global Assessment score of 0 or 1 at week 16, with these benefits maintained over the longer term. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-020-01357-1DOI Listing

Expression of miR-135b in Psoriatic Skin and Its Association with Disease Improvement.

Cells 2020 Jul 2;9(7). Epub 2020 Jul 2.

Dermatology Department, Instituto de Investigación Sanitaria Hospital Universitario de la Princesa (IISP), 28006 Madrid, Spain.

miRNAs have been associated with psoriasis since just over a decade. However, we are far from a complete understanding of their role during the development of this disease. Our objective was to characterize the cutaneous expression of miRNAs not previously described in psoriasis, the changes induced following the treatment with biologicals and their association with disease improvement. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cells9071603DOI Listing

The relationship between sleep disturbance, symptoms and daytime functioning in psoriasis: a prospective study integrating actigraphy and experience sampling methodology.

Sleep Med 2020 Mar 23;72:144-149. Epub 2020 Mar 23.

Sleep and Circadian Neuroscience Institute, Nuffield Department of Clinical Neurosciences, University of Oxford, UK.

Objective/background: Sleep disturbance is common in individuals with psoriasis and appears to be related to both physical and psychological factors. We sought to examine whether psoriasis symptoms, night-time arousal and low mood predicted subsequent objective and self-reported sleep; and whether objective and self-reported sleep predicted next-day psoriasis symptoms and day-time functioning.

Participants/methods: A total of 19 individuals (Female: 11 [57. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.sleep.2020.03.013DOI Listing

Indoor salt water baths followed by artificial ultraviolet B-light for chronic plaque psoriasis: abridged Cochrane review.

Br J Dermatol 2020 Jul 6. Epub 2020 Jul 6.

Department of Dermatology, Ruhr-Universität Bochum, Bochum, Germany.

It has been suggested that indoor salt water baths with exposure to artificial UVB, may benefit patients with psoriasis. Artificial exposure to ultraviolet B-light (UVB) while soaking in an indoor salt bath, also called balneophototherapy, could simulate the natural exposure to the sun while bathing in the Dead Sea. However, the evidence underlying clinical efficacy, such as longer remission from disease and higher dermatology-related quality of life, has not yet been clearly evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.19385DOI Listing

Facile skin targeting of a thalidomide analog containing benzyl chloride moiety alleviates experimental psoriasis via the suppression of MAPK/NF-κB/AP-1 phosphorylation in keratinocytes.

J Dermatol Sci 2020 Jun 21. Epub 2020 Jun 21.

Pharmaceutics Laboratory, Graduate Institute of Natural Products, Chang Gung University, Kweishan, Taoyuan, Taiwan; Research Center for Food and Cosmetic Safety and Research Center for Chinese Herbal Medicine, Chang Gung University of Science and Technology, Kweishan, Taoyuan, Taiwan; Department of Anesthesiology, Chang Gung Memorial Hospital, Kweishan, Taoyuan, Taiwan. Electronic address:

Background: Thalidomide can be a TNF-α inhibitor for treating skin inflammation. This drug exhibits a strong toxicity that limits its application.

Objective: We synthesized a thalidomide analog containing the benzyl chloride group (2-[1-(3-chlorobenzyl)-2,6-dioxopiperidin-3-yl]isoindoline-1,3-dione, CDI) to examine anti-inflammatory activity against psoriasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdermsci.2020.05.013DOI Listing

Lichen planopilaris coexisting with plaque psoriasis effectively treated with brodalumab.

Dermatol Ther 2020 Jul 4:e13967. Epub 2020 Jul 4.

Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.13967DOI Listing

Meningoradiculitis due to varicella zoster virus reactivation in a patient treated with ixekizumab.

Ann Dermatol Venereol 2020 Jun 30. Epub 2020 Jun 30.

Dermatology department, Jean-Bernard hospital, Valenciennes, France.

Introduction: Ixekizumab is a recently developed biopharmaceutical used since 2016 in the US and Europe for the treatment of plaque psoriasis. Few adverse effects have been reported in the literature and ixekizumab is not known to increase the risk of viral reactivation. Herein we report the case of an immunocompetent female patient treated with ixekizumab who presented meningoradiculitis due to varicella zoster virus (VZV) reactivation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annder.2020.04.020DOI Listing

Sex-related impairment and patient needs/benefits in anogenital psoriasis: Difficult-to-communicate topics and their impact on patient-centred care.

PLoS One 2020 1;15(7):e0235091. Epub 2020 Jul 1.

Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.

Genital psoriasis affects 2-5% of psoriasis patients; generalised plaque or intertriginous psoriasis also affects the genital area in 29-40% of cases. Anogenital psoriasis has been associated with significant quality of life impairments, but little is known about specific patient needs/treatment goals. This study aimed to examine the overall and sex-related disease burden, patient needs and treatment benefits in patients with anogenital psoriasis, compared to patients with psoriasis not affecting the anal/genital areas. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0235091PLOS

Immunohistochemical expression of BCAP 31 in chronic plaque psoriasis.

J Immunoassay Immunochem 2020 Jul 1:1-12. Epub 2020 Jul 1.

Faculty of Medicine, Menoufia University , Shebein Elkom, Egypt.

Psoriasis is a common chronic skin inflammatory disease characterized by an exaggerated proliferation of keratinocytes. B-cell receptor-associated protein 31 (BCAP 31) plays critical roles in induction of proliferation and apoptosis. The current study aimed at evaluation of the immunohistochemical localization of BCAP 31 in psoriatic skin compared to normal skin in addition of correlating BCAP31 expression with the clinical and pathological parameters of psoriasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15321819.2020.1785493DOI Listing

Impact of Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045% in the Management of Plaque Psoriasis in Adults.

Clin Cosmet Investig Dermatol 2020 11;13:391-398. Epub 2020 Jun 11.

University of California, San Francisco, Department of Dermatology, San Francisco, CA, USA.

Halobetasol propionate and tazarotene lotion 0.01%/0.045% (HP/TAZ) is a topical medication approved for the treatment of plaque psoriasis in adults. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CCID.S252426DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295208PMC

Higher Serum Selenoprotein P Level as a Novel Inductor of Metabolic Complications in Psoriasis.

Int J Mol Sci 2020 Jun 28;21(13). Epub 2020 Jun 28.

Department of Dermatology and Venereology, Medical University of Bialystok, Zurawia 14 St, 15-540 Bialystok, Poland.

Selenoprotein P (SeP), a member of hepatokines, is involved in the development of various metabolic diseases closely related to psoriasis, but it has not been explored in that dermatosis so far. The study aimed to evaluate the clinical value of serum SeP concentrations in patients with psoriasis and its interplay between disease activity, metabolic or inflammatory parameters and systemic therapy. The study included thirty-three patients with flared plaque-type psoriasis and fifteen healthy volunteers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms21134594DOI Listing

Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States.

J Dermatolog Treat 2020 Jun 30:1-9. Epub 2020 Jun 30.

Southern California Clinical and Translational Science Institute, Los Angeles, CA, USA.

To evaluate the relative cost-effectiveness of tildrakizumab and other biologic and targeted systemic treatments compared with a mix of topical therapies, phototherapies, and other conventional systemic therapies as first-line treatment for moderate-to-severe plaque psoriasis from a United States payer's perspective. A Markov model consisting of health states based on Psoriasis Area Severity Index (PASI) response rate categories and death was developed. The probabilities of achieving PASI responses were derived from a network meta-analysis based on published efficacy data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09546634.2020.1773382DOI Listing

Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.

J Dermatol Sci 2020 Jun 18. Epub 2020 Jun 18.

Medical Affairs, Kyowa Kirin Co., Ltd., Tokyo, Japan.

Background: Complete lesion clearance is important to patients with psoriasis.

Objective: To conduct a network meta-analysis of randomized controlled trials of biologic agents available for psoriasis in Japan, using mixed-treatment comparisons.

Methods: MEDLINE and EMBASE were searched to identify randomized clinical trials (placebo-controlled or head-to-head) of infliximab, adalimumab, ustekinumab, secukinumab, ixekizumab, brodalumab, risankizumab or guselkumab in adult patients with moderate-to-severe plaque psoriasis published in English between 01 January 2000 and 31 August 2019. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdermsci.2020.06.003DOI Listing

[Muramyldipeptide - based compounds in current medicine: focus on glucosaminylmuramyl dipeptide].

Ter Arkh 2019 Dec 15;91(12):122-127. Epub 2019 Dec 15.

Peoples' Friendship University of Russia (RUDN University).

The role of immune mechanisms in the pathogenesis of almost all human diseases shown in recent decades, increase in antibiotic resistance and secondary immunodeficiency, aging of the population and widespread use of immunosuppressive drugs and procedures suggest a wider use of immunomodulators in current clinical practice, but the use of most of them limits the lack of knowledge. The most promising compounds for the development as immunomodulating agents and adjuvants for a wide range of vaccines are low molecular weight fragments of peptidoglycan - muramylpeptides. The article describes the mechanisms of action of muramylpeptides, their biological effects and properties of medicines developed on their basis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26442/00403660.2019.12.000471DOI Listing
December 2019

Development and Characterization of a Clobetasol Propionate Nanostructured Lipid Carrier-based Gel for the Treatment of Plaque Psoriasis.

Curr Mol Pharmacol 2020 Jun 28. Epub 2020 Jun 28.

Department of Pharmaceutics; I.S.F. College of Pharmacy, GhalKalan, Ferozpur, G.T road, Moga-146001, Punjab. India.

Background: Psoriasis is an autoimmune disease of the skin with lapsing episodes of hyperkeratosis, irritation, and inflammation. Numerous traditional and novel drug delivery systems have been used for better penetration through psoriatic barrier cells and also for retention in the skin. As there is no effective remedy for better penetration and retention is there because of the absence of an ideal carrier for effective and safe delivery of antipsoriatic drugs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1874467213666200628135552DOI Listing

Novel Therapeutic Approaches And Targets For Treatment Of Psoriasis.

Curr Pharm Biotechnol 2020 06 29. Epub 2020 Jun 29.

Dermatological Clinic, Depatment of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona. Italy.

Background: Psoriasis is a multifactorial immune-mediated inflammatory disease, with a chronic relapsingremitting course, which affects 2-3% of the worldwide population. Psoriasis involves skin, joints, or both and it is associated with several comorbidities, including metabolic, rheumatological, cardiovascular, psychiatric complications and other chronic inflammatory diseases, which are the expression of the complex underlying pathogenetic mechanism. An accurate characterization of the immune pathways involved in psoriasis led to recognize the new molecules, interleukin (IL)17 and 23, which become the new target of biologic therapy for moderate-to-severe plaque psoriasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1389201021666200629150231DOI Listing

Real-World Experience with Apremilast in the Treatment of Adults with Moderate to Severe Plaque Psoriasis in Québec: A Claims-Based Analysis of Drug Utilization and Healthcare Resource Utilization.

J Cutan Med Surg 2020 Jun 29:1203475420936652. Epub 2020 Jun 29.

5622 Hôpital Hôtel-Dieu de Québec and Pharmacoeconomics and Outcomes Research, PeriPharm Inc., Montréal, Canada.

Background: In Québec, targeted biologic therapies for moderate to severe plaque psoriasis are restricted to patients who have not responded to phototherapy or conventional systemic treatment, primarily due to high drug costs. Apremilast, an oral treatment for plaque psoriasis, was added to the Québec provincial health insurance plan (Régie de l'assurance maladie du Québec; RAMQ) formulary in 2015, making this the only province in Canada with public drug plan reimbursement for apremilast.

Objectives: The aim of this study is to describe patients' characteristics, treatment patterns, healthcare resource utilization (HCRU), and associated costs and to measure real-world budget impact of using apremilast before biologics in plaque psoriasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475420936652DOI Listing

Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): Results from a phase 3, randomised, open-label, efficacy assessor-blinded clinical trial.

Br J Dermatol 2020 Jun 28. Epub 2020 Jun 28.

Paul Sabatier University and Larrey Hospital, Toulouse, France.

Background: Patients with plaque psoriasis treated with biologic therapies need more efficacious, safe, and convenient treatments to improve quality of life. Risankizumab and secukinumab inhibit interleukin (IL)-23 and IL-17A, respectively, and are effective in adult patients with moderate-to-severe plaque psoriasis but have different dosing regimens.

Objectives: Directly compare efficacy and safety of risankizumab vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.19341DOI Listing

Efficacy of Brodalumab for Moderate to Severe Plaque Psoriasis: A Canadian Network Meta-analysis.

J Cutan Med Surg 2020 Jun 26:1203475420933174. Epub 2020 Jun 26.

468790 Probity Medical Research Inc. and K. Papp Clinical Research Inc., Waterloo, ON, Canada.

Background: Several treatments for plaque psoriasis are available, but it remains challenging for physicians to make informed treatment decisions due to a lack of head-to-head trials.

Objectives: This network meta-analysis (NMA) compares the efficacy of brodalumab to other biologic agents in Canada for moderate-to-severe plaque psoriasis.

Methods: A systematic literature review of randomized controlled trials (RCTs) published before October 2017 was conducted to populate the NMA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475420933174DOI Listing

IL-17A in the Psoriatic Patients' Serum and Plaque Scales as Potential Marker of the Diseases Severity and Obesity.

Mediators Inflamm 2020 5;2020:7420823. Epub 2020 Jun 5.

Chair and Department of Dermatology, Venereology and Pediatric Dermatology, Medical University of Lublin, ul. Staszica 16, 20-081 Lublin, Poland.

The aim of the study was to evaluate concentrations of IL-17 in the serum and plaque scales of psoriatic patients. We analyzed their association with the clinical activity of the disease and with body mass index (BMI). Demographic data, medical history, serum, and scale from psoriatic plaques for assessment of IL-17 were collected from all the participants. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2020/7420823DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293749PMC

Apremilast for psoriasis treatment.

G Ital Dermatol Venereol 2020 Jun 15. Epub 2020 Jun 15.

Dermatology Department, Hospital Universitari Germans Trias i Pujol. Universitat Autònoma of Barcelona, Badalona, Spain.

Apremilast is a small-molecule inhibitor of phosphodiesterase 4 with an intracellular mechanism of action that increases levels of cyclic adenosine monophosphate (cAMP) indicated for the oral treatment of moderate to severe plaque psoriasis and for the treatment of psoriatic arthritis. Efficacy of apremilast in moderate-to-severe psoriasis has been demonstrated in the pivotal trials, with a 30% PASI-75 response rate at week 16, an efficacy that was maintained through week 52. Apremilast also achieved significant responses in disease involving specific sites, such as palmoplantar, nail and scalp psoriasis, improved patient quality of life, and achieved rapid improvements in pruritus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.23736/S0392-0488.20.06684-5DOI Listing

Higher Prevalence of Periodontitis and Decayed, Missing and Filled Teeth in Patients with Psoriasis.

Eur J Dent 2020 Jun 15. Epub 2020 Jun 15.

Department of Periodontology, Faculty of Dentistry, Rio de Janeiro State University, Rio de Janeiro, Brazil.

Objective:  The aim of this study is to describe the prevalence and severity of periodontitis and decayed, missing and filled teeth (DMFT) index in patients with psoriasis. As a secondary aim, verify if periodontitis was a risk indicator for psoriasis.

Materials And Methods:  A total of 69 patients diagnosed with psoriasis (48. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0040-1713465DOI Listing

Secukinumab retreatment associated psoriasis flare with pustules.

J Dermatolog Treat 2020 Jun 19:1-4. Epub 2020 Jun 19.

Department of Dermatology, Faculty of Medicine, Cairo University, Cairo, Egypt.

This case report describes a patient with plaque psoriasis and psoriatic arthritis who experienced IL-17A blocking antibody secukinumab treatment-interruption followed by re-treatment. The patient showed heterogeneous responses; significant improvement at initial introduction of secukinumab with rapid deterioration after discontinuation, followed by worsening symptoms and pustular eruption with reintroduction, and skin clearance after dose escalation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09546634.2020.1782816DOI Listing

Staphylococcal toxic shock syndrome in a child with interleukin-17 inhibitor treatment for psoriasis.

Pediatr Dermatol 2020 Jun 13. Epub 2020 Jun 13.

Department of Pediatric Emergency Care, Hospital Universitario La Paz, Madrid, Spain.

A 6-year-old girl presented with fever, skin rash, anuria, and conjunctivitis that rapidly progressed to toxic shock syndrome. Following hospital discharge, she developed a staphylococcal abscess on the lower extremity. She had recently received the first two doses of the interleukin-17 (IL-17) inhibitor secukinumab for resistant plaque psoriasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pde.14228DOI Listing

Plaque-Type Psoriasis Treated with Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam: A Prospective Study on Clinical and Dermoscopic Predictor Factors in Response Achievement and Retention.

Dermatol Ther (Heidelb) 2020 Jun 12. Epub 2020 Jun 12.

Department of Medical Area, Institute of Dermatology, University of Udine, Udine, UD, Italy.

Introduction: Little information on possible local factors that can influence the achievement and retention of response of plaque-type psoriasis to calcipotriene plus betamethasone dipropionate aerosol foam is available. The aim of this study was to assess possible correlations between baseline clinical/dermoscopic features of psoriatic plaques and therapeutic response, and between residual dermoscopic findings in clinically improved/healed lesions and post-treatment relapse.

Methods: For each target lesion, we calculated the local psoriasis severity index and assessed dermoscopic findings at baseline and at the end of a 4-week treatment, correlating the therapeutic outcome with the initial clinical and dermoscopic features. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13555-020-00406-7DOI Listing

Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled Analysis over 3 Years from Three Phase 3, Randomised, Placebo-Controlled Studies.

Br J Dermatol 2020 Jun 12. Epub 2020 Jun 12.

Centre for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Background: Certolizumab pegol (CZP) is an Fc-free, PEGylated anti-tumour necrosis factor biologic.

Objective: Report three-year safety from three phase 3 trials of CZP in adults with plaque psoriasis (PSO).

Methods: Data were pooled from CIMPASI-1 (NCT02326298), CIMPASI-2 (NCT02326272), CIMPACT (NCT02346240). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.19314DOI Listing

Interleukin 23p19 inhibitors in chronic plaque psoriasis with focus on mirikizumab: A narrative review.

Dermatol Ther 2020 Jun 12:e13800. Epub 2020 Jun 12.

Department of Dermatology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.

Psoriasis, a T-cell mediated chronic dermatosis, has a complex etiopathogenesis. There has been extensive research into the aberrant immune response, which leads to the formation of clinical lesions, and the need for developing better and safer drugs has been unrelenting. The past two decades of research has opened up new areas of the immune pathway that can be targeted in order to control the disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.13800DOI Listing
June 2020
1.478 Impact Factor

What are the barriers to physical activity in patients with chronic plaque psoriasis?

Authors:
P Jarrett

Br J Dermatol 2020 Jun 10. Epub 2020 Jun 10.

Department of Dermatology, Middlemore Hospital and Department of Medicine, The University of Auckland, Auckland, New Zealand.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.19209DOI Listing

Physical activity engagement and responses to exercise in plaque psoriasis: a multifactorial investigation of influential factors.

J Dermatolog Treat 2020 Jun 22:1-7. Epub 2020 Jun 22.

Human Movement Sciences Department, Old Dominion University, Norfolk, VA, USA.

Psoriasis may increase the risk of physical inactivity, but few studies have evaluated the etiology. To identify barriers to and predictors of physical activity in psoriasis. Twenty individuals with psoriasis (PsO) and 23 controls recorded activity with accelerometers and completed self-paced 20-min treadmill bouts. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09546634.2020.1781756DOI Listing

Interleukin-9 serves as a key link between systemic inflammation and angiogenesis in psoriasis.

Clin Exp Dermatol 2020 Jun 9. Epub 2020 Jun 9.

Department of Biochemistry, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.

Background: Psoriasis is a T-helper cell mediated chronic immune mediated inflammatory disease affecting mainly the skin, although systemic pathological effects are also observed. Cytokine-mediated interaction between T lymphocytes and keratinocytes lead to excessive proliferation of keratinocytes, which in turn leads to formation of a pro-inflammatory milieu and finally to psoriatic plaque formation. This study was designed to study Interleukin (IL)-9, IL-17 and vascular endothelial growth factor (VEGF) levels in psoriasis patients in comparison to controls and to evaluate the effect of methotrexate monotherapy on the aforesaid cytokine levels in psoriasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ced.14335DOI Listing

Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era.

Expert Opin Biol Ther 2020 Jun 16:1-2. Epub 2020 Jun 16.

Dermatology Unit, Fondazione Policlinico Tor Vergata , Rome, Italy.

Introduction: In light of the current Covid-19 pandemic and the ongoing, extensive debate about the use of biological agents in psoriatic patients, we felt compelled to relate our experience in the use of secukinumab in the same cohort before and during the lockdown in Italy. : Secukinumab was not discontinued, and there were no cases of confirmed infection with SARS-CoV-2 in this cohort. : In our practice, there is no evidence favoring the discontinuation of secukinumab in these patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2020.1779217DOI Listing

Long-term Single Center Experience in Treating Plaque Psoriasis With Guselkumab.

J Cutan Med Surg 2020 Jun 8:1203475420932514. Epub 2020 Jun 8.

SKiN Centre for Dermatology, Peterborough, ON, Canada.

Background: Clinical trial data have shown guselkumab, an interleukin-23 inhibitor, to be efficacious and safe for the treatment of psoriasis. However, there is very little real-world experience using guselkumab in the community setting that has been documented.

Objectives: The goal of this study was to determine real-life outcomes of guselkumab use in patients with moderate-to-severe psoriasis in a community dermatology practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475420932514DOI Listing

Excimer laser for psoriasis treatment: A case report and short review.

Exp Ther Med 2020 Jul 14;20(1):52-55. Epub 2020 Feb 14.

'Dunărea de Jos' University, Clinical Department, 800008 Galați, Romania.

Psoriasis is a common cutaneous disease that has major implications in the quality of life of the patient. It is characterised by a chronic course and in some subtypes, it can be life threatening. Many studies have focused on the pathogenesis concerning this disease therefore improving the therapeutic approaches. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/etm.2020.8529DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271705PMC

Management of Plaque Psoriasis With Biologic Therapies in Women of Child-Bearing Potential Consensus Paper.

J Cutan Med Surg 2020 Jul/Aug;24(1_suppl):3S-14S. Epub 2020 Jun 5.

Department of Medicine, McMaster University, Hamilton, ON, Canada.

Background: Plaque psoriasis (PsO) is a chronic inflammatory disease that often presents at peak reproductive age in women of child-bearing potential (WOCBP). With the emergence of biologic therapies to treat PsO, guidance on disease management in WOCBP is needed to inform treatment decisions before, during, and after pregnancy.

Objectives: To develop a practical, up-to-date consensus document, based on available evidence and expert opinion where evidence was lacking, in order to guide both Canadian and international clinicians treating PsO in WOCBP. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475420928376DOI Listing

TNFα and Reactive Oxygen Signaling in Vascular Smooth Muscle Cells in Hypertension and Atherosclerosis.

Am J Hypertens 2020 Jun 5. Epub 2020 Jun 5.

Division of Pediatric Critical Care, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN.

Hypertension and atherosclerosis, the predecessors of stroke and myocardial infarction, are chronic vascular inflammatory reactions. Tumor necrosis factor alpha (TNFα), the "master" pro-inflammatory cytokine, contributes to both the initiation and maintenance of vascular inflammation. TNFα induces reactive oxygen species (ROS) production which drives the redox reactions that constitute "ROS signaling". Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ajh/hpaa089DOI Listing

The influence of body weight of patients with chronic plaque psoriasis on biological treatment response.

Postepy Dermatol Alergol 2020 Apr 5;37(2):168-173. Epub 2020 May 5.

Department of Dermatology, Venereology and Allergology, Medical University of Gdansk, Gdansk, Poland.

Psoriasis is a chronic inflammatory disease of the skin. The new era of biological therapies initiated a shift in the definition of the disease therapeutic success, however, recent reports in the literature draw attention to the treatment-induced weight gain in psoriatic patients. Therefore, it is worth considering the body mass index influence on the biological treatment of chronic plaque psoriasis, seeing that it has manifold associations with the disease and may play an important role in clinical practice management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5114/ada.2020.94835DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262805PMC

Halobetasol 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Males and Females.

J Drugs Dermatol 2020 May;19(5):504-514

Background: Previous results from two phase 3 studies demonstrated efficacy and safety of fixed combination halobetasol propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion in participants with moderate-to-severe plaque psoriasis. Read More

View Article

Download full-text PDF

Source

A case report of Hodgkin lymphoma in a patient treated with ustekinumab for psoriasis.

Medicine (Baltimore) 2020 May;99(21):e20048

Hematology Unit, First Department of Internal Medicine, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Rationale: Ustekinumab is a biological agent that inhibits interleukin 12 and 23 and has been approved for the treatment of moderate and severe plaque psoriasis. There have been case reports that raise concerns about its oncogenic potential. We are the first authors to report a case of Hodgkin lymphoma in a psoriatic patient receiving ustekinumab. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000020048DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249998PMC

Cost per responder for guselkumab versus secukinumab in the United States based on a head-to-head trial of moderate to severe plaque psoriasis.

J Dermatolog Treat 2020 Jun 4:1-7. Epub 2020 Jun 4.

Real World Value & Evidence, Janssen Scientific Affairs LLC, Horsham, PA, USA.

To estimate cost per response (CPR) in the United States and number-needed-to-treat (NNT) among subjects receiving guselkumab or secukinumab for moderate to severe plaque psoriasis. Results from ECLIPSE, a double-blind, head-to-head, 48-week study of guselkumab compared with secukinumab were used to estimate 48-week, annual induction, and maintenance year CPRs for Psoriasis Area and Severity Index (PASI) 75, 90, and 100 responses for all patients and for PASI 90 response in patients according to previous systemic treatment. Week 48 PASI 90 response rates were 84. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09546634.2020.1770172DOI Listing

Simultaneous Bullous Pemphigoid and Vitiligo Associated with Adalimumab Therapy in a Patient with Psoriasis Vulgaris.

Indian Dermatol Online J 2020 Mar-Apr;11(2):229-231. Epub 2020 Mar 9.

Department of Dermatology, Hospital General de México, Ciudad de México, CDMX, Mexico.

Antitumor necrosis factors (TNFs) agents are increasingly being used for the effective treatment of diverse diseases. Due to its extensive use and longer duartion of treatment, there are a growing number of reports of the development of autoimmune conditions such as systemic lupus erythematosus, bullous pemphigoid (BP), and vitiligo associated with the use of anti-TNF agents. We describe a patient who developed BP as well as vitiligo after receiving treatment with adalimumab for plaque psoriasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/idoj.IDOJ_53_19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247621PMC

Real-life Efficacy and Safety of Biosimilar Adalimumab (ZRC-3197) in Patients with Plaque Psoriasis: A Tertiary Care Center Experience.

Indian Dermatol Online J 2020 Mar-Apr;11(2):182-186. Epub 2020 Mar 9.

Department of Dermatology, Base Hospital Delhi Cantt, New Delhi, India.

Background: Adalimumab is proven to be safe and effective in treating plaque psoriasis. A biosimilar adalimumab (ZRC-3197; Exemptia™) - approved by Indian Regulators in 2014 - is a 'fingerprint match' of the reference adalimumab in terms of purity, potency, safety, and clinical efficacy. While reference adalimumab remains unavailable, this biosimilar adalimumab (bADA) serves as an accessible, cost-effective option for Indian patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/idoj.IDOJ_120_19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247647PMC

Effective use of oral tofacitinib and phototherapy in a patient with concomitant alopecia areata, vitiligo, and plaque and inverse psoriasis.

Clin Case Rep 2020 May 27;8(5):819-822. Epub 2020 Feb 27.

Department of Dermatology Warren Alpert Medical School Brown University Providence RI USA.

This case presentation suggests that tofacitinib combined with phototherapy may be an effective treatment option for patients with concomitant alopecia areata, vitiligo, and different phenotypes of psoriasis including plaque and inverse psoriasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ccr3.2759DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250974PMC

Bimekizumab for patients with moderate-to-severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled phase 2b extension study.

J Am Acad Dermatol 2020 May 28. Epub 2020 May 28.

Salford Royal Hospital, University of Manchester, Manchester NIHR Biomedical Research Centre, Manchester, UK.

Background: Dual neutralization of both interleukin-17A and interleukin-17F with the monoclonal antibody bimekizumab may have greater efficacy in psoriasis than neutralization of interleukin-17A alone.

Objective: To provide longer-term efficacy and safety data for bimekizumab from a phase 2b extension study in patients with moderate-to-severe psoriasis (BE ABLE 2, NCT03010527).

Methods: After the 12-week initial study (BE ABLE 1), patients who had a Psoriasis Area and Severity Index (PASI) 90 response at week 12 received bimekizumab 64 mg, 160 mg, or 320 mg for an additional 48 weeks (60 weeks in total). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.05.105DOI Listing

UVA1 phototherapy as a treatment option for plaque psoriasis in HIV-positive patients.

Photodermatol Photoimmunol Photomed 2020 May 30. Epub 2020 May 30.

Dermatology Unit, ASST Spedali Civili , University of Brescia, Brescia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/phpp.12581DOI Listing

Angiopoietin-like protein 2 in psoriasis: a new linkage with metabolic syndrome.

Postepy Dermatol Alergol 2020 Feb 9;37(1):86-91. Epub 2020 Mar 9.

Department of Dermatology, Venereology and Andrology, Faculty of Medicine, BenhaUniversity, Benha, Egypt.

Introduction: Psoriasis is a chronic disease of inflammatory nature which can be considered as a systemic disorder. Metabolic syndrome is prevalent in psoriatic patients, with a negative impact on disease severity. Angiopoietin-like protein 2 (ANGPTL2) role has been investigated in several chronic inflammatory conditions, but not in psoriasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5114/ada.2018.79225DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247078PMC
February 2020

Brodalumab in the treatment of chronic plaque psoriasis.

Expert Opin Biol Ther 2020 Jun 16:1-11. Epub 2020 Jun 16.

Department of Medicine, Section of Dermatology and Venereology, University of Verona , Verona, Italy.

Introduction: A number of highly selective biologic therapies that target specific immunological pathways of psoriasis have emerged, including molecules that target interleukin (IL)-17. IL-17 has been identified as a key effector pathogenic cytokine in psoriasis, and validated as a highly effective therapeutic target for the treatment of plaque psoriasis.

Area Covered: This review examines the therapeutic efficacy and safety of IL-17 inhibitors in plaque psoriasis and provides an overview of the efficacy and safety data of brodalumab compared with other IL-17 inhibitors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2020.1776256DOI Listing

Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials.

Rheumatology (Oxford) 2020 May 25. Epub 2020 May 25.

Department of Dermatology, Mount Sinai Hospital, New York, NY, USA.

Objectives: The aim of this integrated analysis is to evaluate the long-term safety and tolerability of ixekizumab in adults with psoriasis, PsA and axial SpA.

Methods: Integrated safety data from 21 clinical trials are presented by indication in patients who received at least one dose of ixekizumab. Adverse events (AEs) and treatment-emergent adverse events (TEAEs) adjusted incidence rates (IRs) per 100 patient-years (PY) up to 5 years' exposure are reported. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/rheumatology/keaa189DOI Listing